List view / Grid view
ViiV Healthcare is pleased to announce that the U.S. FDA…
ViiV Healthcare is pleased to announce that the U.S. FDA has approved Tivicay® (dolutegravir) 50-mg tablets...
24-week data from Phase III SAILING study...
6 March 2013 | By GlaxoSmithKline
24-week data from Phase III SAILING study...
“These regulatory submissions are an important step for ViiV Healthcare..."
17 December 2012 | By GlaxoSmithKline
“These regulatory submissions are an important step for ViiV Healthcare..."
24-week data from VIKING-3 Phase III study...
13 November 2012 | By GlaxoSmithKline
24-week data from VIKING-3 Phase III study...
Phase III SINGLE study results...
11 July 2012 | By GlaxoSmithKline
Phase III SINGLE study results...
SPRING-2 study meets primary endpoint of non-inferiority of dolutegravir...
2 April 2012 | By GlaxoSmithKline
SPRING-2 study meets primary endpoint of non-inferiority of dolutegravir...
